Literature DB >> 25224142

Microporation is an efficient method for siRNA-induced knockdown of PEX5 in HepG2 cells: evaluation of the transfection efficiency, the PEX5 mRNA and protein levels and induction of peroxisomal deficiency.

Barbara Ahlemeyer1, Julia-Franziska Vogt, Vera Michel, Petra Hahn-Kohlberger, Eveline Baumgart-Vogt.   

Abstract

The pathomechanism of peroxisomal biogenesis disorders (PBDs), a group of inherited autosomal recessive diseases with mutations of peroxin (PEX) genes, is not yet fully understood. Therefore, several knockout models, e.g., the PEX5 knockout mouse, have been generated exhibiting a complete loss of peroxisomal function. In this study, we wanted to knockdown PEX5 using the siRNA technology (1) to mimic milder forms of PBDs in which the mutated peroxin has some residual function and (2) to analyze the cellular consequences of a reduction of the PEX5 protein without adaption during the development as it is the case in a knockout animal. First, we tried to optimize the transfection of the hepatoma cell line HepG2 with PEX5 siRNA using different commercially available liposomal and non-liposomal transfection reagents (Lipofectamine(®) 2000, FuGENE 6, HiPerFect(®), INTERFERin™, RiboJuice™) as well as microporation using the Neon™ Transfection system. Microporation was found to be superior to the transfection reagents with respect to the transfection efficiency (100 vs. 0-70%), to the reduction of PEX5 mRNA (by 90 vs. 0-50%) and PEX5 protein levels (by 70 vs. 0-50%). Interestingly, we detected that a part of the cleaved PEX5 mRNA still existed as 3' fragment (15%) 24 h after microporation. Using microporation, we further analyzed whether the reduced PEX5 protein level impaired peroxisomal function. We indeed detected a reduced targeting of SKL-tagged proteins into peroxisomes as well as an increased oxidative stress as found in PBD patients and respective knockout mouse models. Knockdown of the PEX5 protein and functional consequences were at a maximum 48 h after microporation. Thereafter, the PEX5 protein was resynthesized, which may allow the temporal analysis of the loss as well as the reconstitution of peroxisomes in the future. In conclusion, we propose microporation as an efficient and reproducible method to transfect HepG2 cells with PEX5 siRNA. We succeeded to transiently knockdown PEX5 mRNA and its protein level leading to functional consequences similar as observed in peroxisome deficiencies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25224142     DOI: 10.1007/s00418-014-1254-6

Source DB:  PubMed          Journal:  Histochem Cell Biol        ISSN: 0948-6143            Impact factor:   4.304


  59 in total

1.  Efficient transfection method for primary cells.

Authors:  Astrid Hamm; Nicole Krott; Ines Breibach; Rüdiger Blindt; Anja K Bosserhoff
Journal:  Tissue Eng       Date:  2002-04

2.  The apparent uptake of fluorescently labeled siRNAs by electroporated cells depends on the fluorochrome.

Authors:  Jenny Dunne; Bettina Drescher; Heidemarie Riehle; Philipp Hadwiger; Bryan D Young; Jürgen Krauter; Olaf Heidenreich
Journal:  Oligonucleotides       Date:  2003

3.  Mitochondria are targets for peroxisome-derived oxidative stress in cultured mammalian cells.

Authors:  Bo Wang; Paul P Van Veldhoven; Chantal Brees; Noemí Rubio; Marcus Nordgren; Oksana Apanasets; Markus Kunze; Myriam Baes; Patrizia Agostinis; Marc Fransen
Journal:  Free Radic Biol Med       Date:  2013-08-27       Impact factor: 7.376

4.  Cyclodextrin-containing polycations for nucleic acid delivery.

Authors:  Jeremy D Heidel
Journal:  Cold Spring Harb Protoc       Date:  2011-11-01

5.  A mouse model for Zellweger syndrome.

Authors:  M Baes; P Gressens; E Baumgart; P Carmeliet; M Casteels; M Fransen; P Evrard; D Fahimi; P E Declercq; D Collen; P P van Veldhoven; G P Mannaerts
Journal:  Nat Genet       Date:  1997-09       Impact factor: 38.330

6.  Inhibition of peroxisomal functions due to oxidative imbalance induced by mistargeting of catalase to cytoplasm is restored by vitamin E treatment in skin fibroblasts from Zellweger syndrome-like patients.

Authors:  Yasusada Kawada; Mushfiquddin Khan; Ashish K Sharma; Dinath B Ratnayake; Kazushige Dobashi; Kohtaro Asayama; Hugo W Moser; Miguel A Contreras; Inderjit Singh
Journal:  Mol Genet Metab       Date:  2004-12       Impact factor: 4.797

Review 7.  The use of recombinant adeno-associated virus for skeletal gene therapy.

Authors:  Juan Dai; A Bakr M Rabie
Journal:  Orthod Craniofac Res       Date:  2007-02       Impact factor: 1.826

8.  Analysis of differential lipofection efficiency in primary and established myoblasts.

Authors:  Francesca Pampinella; Delphine Lechardeur; Elena Zanetti; Ian MacLachlan; Mohammed Benharouga; Gergely L Lukacs; Libero Vitiello
Journal:  Mol Ther       Date:  2002-02       Impact factor: 11.454

9.  The generation of NGF-secreting primary rat monocytes: a comparison of different transfer methods.

Authors:  Lindsay A Hohsfield; Stephan Geley; Markus Reindl; Christian Humpel
Journal:  J Immunol Methods       Date:  2013-03-05       Impact factor: 2.303

10.  Persistence of different forms of transient RNAi during apoptosis in mammalian cells.

Authors:  Febitha Kandan-Kulangara; Rashmi G Shah; El Bachir Affar; Girish M Shah
Journal:  PLoS One       Date:  2010-08-18       Impact factor: 3.240

View more
  3 in total

Review 1.  The Histochemistry and Cell Biology pandect: the year 2014 in review.

Authors:  Douglas J Taatjes; Jürgen Roth
Journal:  Histochem Cell Biol       Date:  2015-03-06       Impact factor: 4.304

Review 2.  Opportunities and Challenges in the Delivery of mRNA-based Vaccines.

Authors:  Abishek Wadhwa; Anas Aljabbari; Abhijeet Lokras; Camilla Foged; Aneesh Thakur
Journal:  Pharmaceutics       Date:  2020-01-28       Impact factor: 6.321

3.  Identification and Functional Validation of Radioresistance-Related Genes AHNAK2 and EVPL in Esophageal Squamous Cell Carcinoma by Exome and Transcriptome Sequencing Analyses.

Authors:  Qiang Hou; Zhenzhen Jiang; Ziwei Li; Mingfeng Jiang
Journal:  Onco Targets Ther       Date:  2021-02-18       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.